NO328733B1 - Fosfolipidkomplekser av proantocyanidin A2, farmasoytisk sammensetning inneholdende kompleksene og anvendelse derav - Google Patents

Fosfolipidkomplekser av proantocyanidin A2, farmasoytisk sammensetning inneholdende kompleksene og anvendelse derav Download PDF

Info

Publication number: NO328733B1
Authority: NO; Norway
Prior art keywords: complexes; proanthocyanidin; phospholipid; complex; pharmaceutical composition
Prior art date: 1998-12-18

Application number

NO20012944A

Other languages

English (en)

Norwegian (no)

Other versions

NO20012944L (no

NO20012944D0 (no

Inventor

Ezio Bombardelli

Paolo Morazzoni

Original Assignee

Indena Spa

Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)

1998-12-18

Filing date

2001-06-14

Publication date

2010-05-03

2001-06-14 Application filed by Indena Spa filed Critical Indena Spa

2001-06-14 Publication of NO20012944L publication Critical patent/NO20012944L/no

2001-06-14 Publication of NO20012944D0 publication Critical patent/NO20012944D0/no

2010-05-03 Publication of NO328733B1 publication Critical patent/NO328733B1/no

Links

150000003904 phospholipids Chemical class 0.000 title claims abstract description 19
239000008194 pharmaceutical composition Substances 0.000 title claims abstract description 5
NSEWTSAADLNHNH-TXZJYACMSA-N Proanthocyanidin A-2 Natural products C1([C@H]2OC3=C4[C@H]5C6=C(O)C=C(O)C=C6O[C@]([C@@H]5O)(OC4=CC(O)=C3C[C@@H]2O)C=2C=C(O)C(O)=CC=2)=CC=C(O)C(O)=C1 NSEWTSAADLNHNH-TXZJYACMSA-N 0.000 claims abstract description 22
229920002982 Procyanidin A2 Polymers 0.000 claims abstract description 22
NSEWTSAADLNHNH-UHFFFAOYSA-N pavetannin A-2 Natural products OC1CC2=C(O)C=C3OC(C4O)(C=5C=C(O)C(O)=CC=5)OC5=CC(O)=CC(O)=C5C4C3=C2OC1C1=CC=C(O)C(O)=C1 NSEWTSAADLNHNH-UHFFFAOYSA-N 0.000 claims abstract description 22
NSEWTSAADLNHNH-LSBOWGMISA-N proanthocyanidin A2 Chemical compound C1([C@H]2OC3=C4[C@H]5C6=C(O)C=C(O)C=C6O[C@]([C@@H]5O)(OC4=CC(O)=C3C[C@H]2O)C=2C=C(O)C(O)=CC=2)=CC=C(O)C(O)=C1 NSEWTSAADLNHNH-LSBOWGMISA-N 0.000 claims abstract description 22
201000001320 Atherosclerosis Diseases 0.000 claims abstract description 4
206010008118 cerebral infarction Diseases 0.000 claims abstract description 3
208000026106 cerebrovascular disease Diseases 0.000 claims abstract description 3
230000002107 myocardial effect Effects 0.000 claims abstract description 3
208000010125 myocardial infarction Diseases 0.000 claims abstract description 3
WTJKGGKOPKCXLL-RRHRGVEJSA-N phosphatidylcholine Chemical compound CCCCCCCCCCCCCCCC(=O)OC[C@H](COP([O-])(=O)OCC[N+](C)(C)C)OC(=O)CCCCCCCC=CCCCCCCCC WTJKGGKOPKCXLL-RRHRGVEJSA-N 0.000 claims description 6
239000003814 drug Substances 0.000 claims description 5
229940079593 drug Drugs 0.000 claims description 5
238000011282 treatment Methods 0.000 claims description 5
239000007903 gelatin capsule Substances 0.000 claims description 3
238000002360 preparation method Methods 0.000 claims description 3
TZCPCKNHXULUIY-RGULYWFUSA-N 1,2-distearoyl-sn-glycero-3-phosphoserine Chemical compound CCCCCCCCCCCCCCCCCC(=O)OC[C@H](COP(O)(=O)OC[C@H](N)C(O)=O)OC(=O)CCCCCCCCCCCCCCCCC TZCPCKNHXULUIY-RGULYWFUSA-N 0.000 claims description 2
JZNWSCPGTDBMEW-UHFFFAOYSA-N Glycerophosphorylethanolamin Natural products NCCOP(O)(=O)OCC(O)CO JZNWSCPGTDBMEW-UHFFFAOYSA-N 0.000 claims description 2
ZWZWYGMENQVNFU-UHFFFAOYSA-N Glycerophosphorylserin Natural products OC(=O)C(N)COP(O)(=O)OCC(O)CO ZWZWYGMENQVNFU-UHFFFAOYSA-N 0.000 claims description 2
239000000787 lecithin Substances 0.000 claims description 2
235000010445 lecithin Nutrition 0.000 claims description 2
150000008104 phosphatidylethanolamines Chemical class 0.000 claims description 2
230000001225 therapeutic effect Effects 0.000 claims description 2
239000004480 active ingredient Substances 0.000 claims 2
230000000069 prophylactic effect Effects 0.000 claims 1
HVYWMOMLDIMFJA-DPAQBDIFSA-N cholesterol Chemical compound C1C=C2C[C@@H](O)CC[C@]2(C)[C@@H]2[C@@H]1[C@@H]1CC[C@H]([C@H](C)CCCC(C)C)[C@@]1(C)CC2 HVYWMOMLDIMFJA-DPAQBDIFSA-N 0.000 description 8
XEKOWRVHYACXOJ-UHFFFAOYSA-N Ethyl acetate Chemical compound CCOC(C)=O XEKOWRVHYACXOJ-UHFFFAOYSA-N 0.000 description 6
235000005911 diet Nutrition 0.000 description 6
230000037213 diet Effects 0.000 description 6
230000000260 hypercholesteremic effect Effects 0.000 description 6
241001465754 Metazoa Species 0.000 description 5
230000003143 atherosclerotic effect Effects 0.000 description 5
CSCPPACGZOOCGX-UHFFFAOYSA-N Acetone Chemical compound CC(C)=O CSCPPACGZOOCGX-UHFFFAOYSA-N 0.000 description 4
235000012000 cholesterol Nutrition 0.000 description 4
230000003902 lesion Effects 0.000 description 4
UOTMYNBWXDUBNX-UHFFFAOYSA-N 1-[(3,4-dimethoxyphenyl)methyl]-6,7-dimethoxyisoquinolin-2-ium;chloride Chemical compound Cl.C1=C(OC)C(OC)=CC=C1CC1=NC=CC2=CC(OC)=C(OC)C=C12 UOTMYNBWXDUBNX-UHFFFAOYSA-N 0.000 description 3
208000037260 Atherosclerotic Plaque Diseases 0.000 description 3
239000000203 mixture Substances 0.000 description 3
230000002792 vascular Effects 0.000 description 3
LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 2
241000283973 Oryctolagus cuniculus Species 0.000 description 2
239000003963 antioxidant agent Substances 0.000 description 2
230000002490 cerebral effect Effects 0.000 description 2
JPFCOVZKLAXXOE-XBNSMERZSA-N (3r)-2-(3,5-dihydroxy-4-methoxyphenyl)-8-[(2r,3r,4r)-3,5,7-trihydroxy-2-(4-hydroxyphenyl)-3,4-dihydro-2h-chromen-4-yl]-3,4-dihydro-2h-chromene-3,5,7-triol Chemical compound C1=C(O)C(OC)=C(O)C=C1C1[C@H](O)CC(C(O)=CC(O)=C2[C@H]3C4=C(O)C=C(O)C=C4O[C@@H]([C@@H]3O)C=3C=CC(O)=CC=3)=C2O1 JPFCOVZKLAXXOE-XBNSMERZSA-N 0.000 description 1
-1 3,4-dihydroxyphenyl Chemical group 0.000 description 1
241000157280 Aesculus hippocastanum Species 0.000 description 1
108010028554 LDL Cholesterol Proteins 0.000 description 1
241000283977 Oryctolagus Species 0.000 description 1
229920001991 Proanthocyanidin Polymers 0.000 description 1
108010069201 VLDL Cholesterol Proteins 0.000 description 1
230000000879 anti-atherosclerotic effect Effects 0.000 description 1
230000003035 anti-peroxidant effect Effects 0.000 description 1
230000000767 anti-ulcer Effects 0.000 description 1
230000003078 antioxidant effect Effects 0.000 description 1
210000000709 aorta Anatomy 0.000 description 1
210000000702 aorta abdominal Anatomy 0.000 description 1
210000002376 aorta thoracic Anatomy 0.000 description 1
230000015572 biosynthetic process Effects 0.000 description 1
239000002775 capsule Substances 0.000 description 1
239000003795 chemical substances by application Substances 0.000 description 1
210000000038 chest Anatomy 0.000 description 1
GGCLNOIGPMGLDB-GYKMGIIDSA-N cholest-5-en-3-one Chemical compound C1C=C2CC(=O)CC[C@]2(C)[C@@H]2[C@@H]1[C@@H]1CC[C@H]([C@H](C)CCCC(C)C)[C@@]1(C)CC2 GGCLNOIGPMGLDB-GYKMGIIDSA-N 0.000 description 1
238000007796 conventional method Methods 0.000 description 1
230000001120 cytoprotective effect Effects 0.000 description 1
201000010099 disease Diseases 0.000 description 1
208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 1
238000004821 distillation Methods 0.000 description 1
238000009826 distribution Methods 0.000 description 1
238000009552 doppler ultrasonography Methods 0.000 description 1
230000000694 effects Effects 0.000 description 1
238000009472 formulation Methods 0.000 description 1
238000004817 gas chromatography Methods 0.000 description 1
235000010181 horse chestnut Nutrition 0.000 description 1
238000004519 manufacturing process Methods 0.000 description 1
235000021590 normal diet Nutrition 0.000 description 1
238000012261 overproduction Methods 0.000 description 1
239000002245 particle Substances 0.000 description 1
239000000546 pharmaceutical excipient Substances 0.000 description 1
238000011321 prophylaxis Methods 0.000 description 1
239000011541 reaction mixture Substances 0.000 description 1
235000021003 saturated fats Nutrition 0.000 description 1
230000037390 scarring Effects 0.000 description 1
239000002904 solvent Substances 0.000 description 1
238000003756 stirring Methods 0.000 description 1
239000004094 surface-active agent Substances 0.000 description 1
230000004083 survival effect Effects 0.000 description 1
238000002560 therapeutic procedure Methods 0.000 description 1
150000003626 triacylglycerols Chemical class 0.000 description 1
230000002666 vasoprotective effect Effects 0.000 description 1
230000001643 venotonic effect Effects 0.000 description 1

Classifications

- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/66—Phosphorus compounds
- A61K31/683—Diesters of a phosphorus acid with two hydroxy compounds, e.g. phosphatidylinositols
- A61K31/685—Diesters of a phosphorus acid with two hydroxy compounds, e.g. phosphatidylinositols one of the hydroxy compounds having nitrogen atoms, e.g. phosphatidylserine, lecithin
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
- A61K47/54—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic compound
- A61K47/543—Lipids, e.g. triglycerides; Polyamines, e.g. spermine or spermidine
- A61K47/544—Phospholipids
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
- A61K31/35—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/06—Antihyperlipidemics
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis

Landscapes

Health & Medical Sciences (AREA)
Life Sciences & Earth Sciences (AREA)
Veterinary Medicine (AREA)
Pharmacology & Pharmacy (AREA)
Chemical & Material Sciences (AREA)
Public Health (AREA)
General Health & Medical Sciences (AREA)
Medicinal Chemistry (AREA)
Animal Behavior & Ethology (AREA)
Engineering & Computer Science (AREA)
Bioinformatics & Cheminformatics (AREA)
Molecular Biology (AREA)
Epidemiology (AREA)
Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
General Chemical & Material Sciences (AREA)
Chemical Kinetics & Catalysis (AREA)
Organic Chemistry (AREA)
Diabetes (AREA)
Biophysics (AREA)
Obesity (AREA)
Hematology (AREA)
Heart & Thoracic Surgery (AREA)
Cardiology (AREA)
Vascular Medicine (AREA)
Urology & Nephrology (AREA)
Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Medicinal Preparation (AREA)
Polysaccharides And Polysaccharide Derivatives (AREA)
Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Medicines Containing Plant Substances (AREA)
Medicines Containing Material From Animals Or Micro-Organisms (AREA)
Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)

NO20012944A 1998-12-18 2001-06-14 Fosfolipidkomplekser av proantocyanidin A2, farmasoytisk sammensetning inneholdende kompleksene og anvendelse derav NO328733B1 (no)

Applications Claiming Priority (2)

Application Number	Priority Date	Filing Date	Title
IT1998MI002732A IT1304183B1 (it)	1998-12-18	1998-12-18	Complessi di proantocianidina a2 con fosfolipidi come agentiantiaterosclerotici.
PCT/EP1999/009854 WO2000037062A2 (en)	1998-12-18	1999-12-13	Phospholipid complexes of proanthocyanidin a2 as antiatherosclerotic agents

Publications (3)

Publication Number	Publication Date
NO20012944L NO20012944L (no)	2001-06-14
NO20012944D0 NO20012944D0 (no)	2001-06-14
NO328733B1 true NO328733B1 (no)	2010-05-03

Family

ID=11381268

Family Applications (1)

Application Number	Title	Priority Date	Filing Date
NO20012944A NO328733B1 (no)	1998-12-18	2001-06-14	Fosfolipidkomplekser av proantocyanidin A2, farmasoytisk sammensetning inneholdende kompleksene og anvendelse derav

Country Status (22)

Country	Link
US (1)	US6429202B1 (de)
EP (1)	EP1140115B1 (de)
JP (1)	JP4842436B2 (de)
KR (1)	KR100694907B1 (de)
CN (1)	CN1146429C (de)
AT (1)	ATE238803T1 (de)
AU (1)	AU763907B2 (de)
CA (1)	CA2355776C (de)
CZ (1)	CZ301495B6 (de)
DE (1)	DE69907509T2 (de)
DK (1)	DK1140115T3 (de)
ES (1)	ES2197708T3 (de)
HK (1)	HK1042430B (de)
HU (1)	HU228928B1 (de)
IL (2)	IL143751A0 (de)
IT (1)	IT1304183B1 (de)
NO (1)	NO328733B1 (de)
PL (1)	PL197153B1 (de)
PT (1)	PT1140115E (de)
RU (1)	RU2248798C2 (de)
SK (1)	SK284884B6 (de)
WO (1)	WO2000037062A2 (de)

Families Citing this family (12)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
US8507018B2 (en)	1998-03-12	2013-08-13	Mars, Incorporated	Products containing polyphenol(s) and L-arginine and methods of use thereof
EP1482920B2 (de) *	2002-02-12	2011-07-20	Hunza di Pistolesi Elvira & C. S.a.S.	Zusammensetzungen enthaltend n-acyl-phosphatidyl-ethanolamin und/oder mischungen von n-acyl-ethanolaminen mit phosphatidinsäuren oder lysophosphatidinsäuren
ITMI20020756A1 (it) *	2002-04-09	2003-10-09	Sinclair Pharma S R L	Composizioni farmaceutiche topiche per il trattamento delle dermatiti
GB0321996D0 (en) *	2003-09-19	2003-10-22	Novartis Nutrition Ag	Organic compounds
EP1713467B1 (de) *	2004-01-28	2012-08-01	Mars, Incorporated	Zusammensetzungen und verfahren zur verwendung von procyanidinen vom a-typ
EP1837030A1 (de)	2006-03-09	2007-09-26	INDENA S.p.A.	Curcumin-phospholipid-Komplexe mit verbesserter Bioverfügbarkeit
WO2009104556A1 (ja) *	2008-02-19	2009-08-27	株式会社岐阜セラツク製造所	組成物
IT1398624B1 (it) *	2009-02-02	2013-03-08	Dermogyn S R L	Uso cosmetico della proantocianidina a2
RU2456674C1 (ru) *	2011-05-31	2012-07-20	Тагир Уралович Гафаров	Способ моделирования атрофического рубца кожи
CN102688501A (zh) *	2012-06-20	2012-09-26	浙江萧山医院	原花青素b2磷脂复合物及其制备方法和用途
CN103120798A (zh) *	2013-01-10	2013-05-29	施冬云	一种具有抗氧化应激作用的磷脂复合物制备方法及其应用
CN103467778B (zh) *	2013-09-06	2015-09-30	天津大学	细菌纤维素/卵磷脂复合材料及制备和应用

Family Cites Families (11)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
US4698360B1 (en)	1985-04-09	1997-11-04	D Investigations Pharmacologiq	Plant extract with a proanthocyanidins content as therapeutic agent having radical scavenger effect and use thereof
GB8518289D0 (en) *	1985-07-19	1985-08-29	Inverni Della Beffa Spa	Obtaining proanthocyanidine a2
IT1201149B (it) *	1987-01-14	1989-01-27	Indena Spa	Complessi di bioflavonoidi con fosfolipidi,loro preparazione,uso e composizioni farmaceutici e cosmetiche
IT1201151B (it) *	1987-01-14	1989-01-27	Indena Spa	Complessi fosfolipidici con estratti da vitis vinifera,procedimento per la loro preparazione e composizioni che li cntengono
UA26442C2 (uk) *	1990-08-20	1999-08-30	Герхард Оленшлегер	Фармкомпозиція для профілактики і лікуваhhя захворюваhь, пов'язаhих з порушеhhям обміhу речовиh
US5648377A (en) *	1993-12-21	1997-07-15	Indena S.P.A.	Formulations containing carotenoids an procarotenoids combined with polyphenols in the prevention of the damages due to an abnormal production of free radicals
IT1265312B1 (it) *	1993-12-21	1996-10-31	Indena Spa	Formulazioni contenenti carotenoidi e procarotenoidi associati a polifenoli nella prevenzione dei danni da abnorme produzione di
IT1270999B (it) *	1994-07-26	1997-05-26	Indena Spa	Formulazioni a base di cumarine e loro uso in campo farmaceutico e cosmetico
FI955691A7 (fi)	1994-11-28	1996-05-29	Suntory Ltd	Lipoproteiini(a):ta alentava aine, kolesterolia alentava aine ja näitä aineita sisältävät lääkkeet
IT1296920B1 (it) *	1997-12-04	1999-08-03	Indena Spa	Uso di complessi di estratti vitis vinifera con fosfolipidi come agenti anti-aterosclerotici
EP1210785B1 (de)	1999-09-08	2005-11-23	Siemens Aktiengesellschaft	Anordnung und verfahren für eine optische informationsübertragung

1998
- 1998-12-18 IT IT1998MI002732A patent/IT1304183B1/it active
1999
- 1999-12-13 RU RU2001116085/15A patent/RU2248798C2/ru not_active IP Right Cessation
- 1999-12-13 HU HU0104665A patent/HU228928B1/hu not_active IP Right Cessation
- 1999-12-13 JP JP2000589173A patent/JP4842436B2/ja not_active Expired - Fee Related
- 1999-12-13 IL IL14375199A patent/IL143751A0/xx active IP Right Grant
- 1999-12-13 AT AT99966956T patent/ATE238803T1/de active
- 1999-12-13 CZ CZ20012134A patent/CZ301495B6/cs not_active IP Right Cessation
- 1999-12-13 WO PCT/EP1999/009854 patent/WO2000037062A2/en not_active Ceased
- 1999-12-13 US US09/857,804 patent/US6429202B1/en not_active Expired - Lifetime
- 1999-12-13 AU AU22830/00A patent/AU763907B2/en not_active Ceased
- 1999-12-13 SK SK860-2001A patent/SK284884B6/sk not_active IP Right Cessation
- 1999-12-13 ES ES99966956T patent/ES2197708T3/es not_active Expired - Lifetime
- 1999-12-13 PL PL349534A patent/PL197153B1/pl unknown
- 1999-12-13 HK HK02103200.8A patent/HK1042430B/zh not_active IP Right Cessation
- 1999-12-13 PT PT99966956T patent/PT1140115E/pt unknown
- 1999-12-13 CN CNB998144460A patent/CN1146429C/zh not_active Expired - Fee Related
- 1999-12-13 KR KR1020017007374A patent/KR100694907B1/ko not_active Expired - Fee Related
- 1999-12-13 DK DK99966956T patent/DK1140115T3/da active
- 1999-12-13 EP EP99966956A patent/EP1140115B1/de not_active Expired - Lifetime
- 1999-12-13 DE DE69907509T patent/DE69907509T2/de not_active Expired - Lifetime
- 1999-12-13 CA CA002355776A patent/CA2355776C/en not_active Expired - Fee Related
2001
- 2001-06-13 IL IL143751A patent/IL143751A/en not_active IP Right Cessation
- 2001-06-14 NO NO20012944A patent/NO328733B1/no not_active IP Right Cessation

Also Published As

Publication number	Publication date
NO20012944L (no)	2001-06-14
IL143751A0 (en)	2002-04-21
WO2000037062A3 (en)	2000-08-03
IL143751A (en)	2006-07-05
JP4842436B2 (ja)	2011-12-21
SK284884B6 (sk)	2006-02-02
WO2000037062A2 (en)	2000-06-29
CN1330548A (zh)	2002-01-09
EP1140115A2 (de)	2001-10-10
SK8602001A3 (en)	2001-12-03
HU228928B1 (en)	2013-06-28
DE69907509T2 (de)	2004-04-08
US6429202B1 (en)	2002-08-06
CN1146429C (zh)	2004-04-21
ES2197708T3 (es)	2004-01-01
PL197153B1 (pl)	2008-03-31
ATE238803T1 (de)	2003-05-15
DE69907509D1 (en)	2003-06-05
RU2248798C2 (ru)	2005-03-27
AU763907B2 (en)	2003-08-07
CA2355776C (en)	2008-03-18
IT1304183B1 (it)	2001-03-08
EP1140115B1 (de)	2003-05-02
PT1140115E (pt)	2003-08-29
HK1042430B (zh)	2004-10-08
DK1140115T3 (da)	2003-08-25
HUP0104665A3 (en)	2003-01-28
AU2283000A (en)	2000-07-12
KR20010093826A (ko)	2001-10-29
KR100694907B1 (ko)	2007-03-14
ITMI982732A1 (it)	2000-06-18
CA2355776A1 (en)	2000-06-29
HUP0104665A2 (hu)	2002-04-29
JP2002532543A (ja)	2002-10-02
CZ20012134A3 (cs)	2001-12-12
NO20012944D0 (no)	2001-06-14
CZ301495B6 (cs)	2010-03-24
HK1042430A1 (en)	2002-08-16

Legal Events

Date	Code	Title	Description
2017-07-24	MM1K	Lapsed by not paying the annual fees

Publication	Publication Date	Title
EP0275224B1 (de)	1993-07-21	Phospholipidische Komplexe aus Vitis Vinifera-Extrakten, Verfahren zu ihrer Herstellung und sie enthaltende pharmazeutische und kosmetische Zusammensetzungen
JP3114895B2 (ja)	2000-12-04	炎症性疾患の処置のための薬剤調製物
EP1140115B1 (de)	2003-05-02	Pphospholipidkomplexe von proanthocyanidin a2 als antiatherosklerotische mittel
EP2723345A2 (de)	2014-04-30	Zusammensetzung mit phosphatidylcholin als wirkstoff zur verminderung der toxizität eines antikrebsmittels
US6297218B1 (en)	2001-10-02	Phospholipid complexes prepared from extracts of Vitis vinifera as anti-atherosclerotic agents
Hosford et al.	1988	Natural antagonists of platelet‐activating factor
JPH1067656A (ja)	1998-03-10	細胞接着抑制剤
JP2004518639A (ja)	2004-06-24	塩化物分泌を増加しそして炎症を阻害するためのイノシトール誘導体
JPWO2002078685A1 (ja)	2004-08-19	血管障害疾患用剤
HU195503B (en)	1988-05-30	Process for preparing flavolignane derivatives and pharmaceutical compositions containing them
JP2002509532A (ja)	2002-03-26	アルグラビン（ａｒｇｌａｂｉｎ）およびアルグラビン誘導体の薬学的組成物
JPS6217598B2 (de)	1987-04-18
AU2009258014A1 (en)	2009-12-17	Anticancer methods using extracts of Anemarrhena asphodeloides Bunge
CZ278542B6 (en)	1994-03-16	1,5-bis(3-beta-d-glucosyloxy-4-hydroxyphenyl)pent-1-en-4-ine, process of its isolation and a preparation based thereon
JPS6259119B2 (de)	1987-12-09
PL375295A1 (pl)	2006-11-27	Zastosowanie genisteiny do leczenia łuszczycy i środek farmaceutyczny do leczenia łuszczycy
EP3845222A1 (de)	2021-07-07	Mikroverkapselte formulierung mit diosmin, troxerutin und cumarinen, zusammensetzungen davon und verwendung davon zur behandlung von kreislauferkrankungen
JPWO1996024575A1 (ja)	1998-02-24	肝疾患予防治療剤